ArticleNPJ Parkinson's disease2026
Cardiac sympathetic degeneration informs the duration of the prodromal stage of body-first Lewy body disease.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Body-first Lewy body disease (LBD) is hypothesized to begin in the peripheral autonomic nervous system years before nigrostriatal involvement. Isolated REM sleep behaviour disorder (iRBD) is considered an early manifestation of body-first LBD but is preceded by an unknown period of peripheral autonomic degeneration. Consequently, the total duration of the prodromal phase remains unknown. We used longitudinal imaging data to model the progression of cardiac sympathetic and nigrostriatal dopaminergic degeneration and employed the resulting curves to estimate the prodromal period of body-first LBD. Cardiac sympathetic trajectories were highly consistent across two cohorts, showing rapid early decline followed by gradual slowing, reaching 50% of the normal value after ~5 years and 25% after ~10 years. Dopaminergic decline was slightly slower, reaching 50% of the normal value after ~8 years and 25% after ~15 years. iRBD patients displayed severe baseline cardiac sympathetic loss (median 21.3% of normal), but mild baseline dopaminergic deficit (median 81.5% of normal), indicating that cardiac sympathetic degeneration may precede dopaminergic nigrostriatal involvement by 8.6 years. Based on baseline dopaminergic deficits in Parkinson's disease (PD), the combined model estimated that the prodromal phase of body-first LBD, from onset of cardiac sympathetic degeneration to predicted clinical PD diagnosis, exceeds 20 years.
Identifiers
42386728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.